PET Community And FDA Move Forward In Inspection, Drug Application Talks
This article was originally published in The Gray Sheet
Executive Summary
Final regulations governing the manufacture of radiopharmaceutical chemicals for use with positron emission tomography will not be in place by the November 1999 deadline mandated by the FDA Modernization Act, according to officials from FDA's Center for Drug Evaluation and Research.
You may also be interested in...
PET Drugs cGMP Proposed Rule, Guidance To Be Refined By CDER
FDA plans to clarify the quality control section of its preliminary draft proposed rule and proposed guidance for positron emission tomography (PET) radiopharmaceutical current good manufacturing practices
PET Drugs cGMP Proposed Rule, Guidance To Be Refined By CDER
FDA plans to clarify the quality control section of its preliminary draft proposed rule and proposed guidance for positron emission tomography (PET) radiopharmaceutical current good manufacturing practices
FDA Panel Tables Recommendation On O-15 Imaging Agent, Okays F-18, N-13
Additional information is needed to support FDA approval of water O-15 injection as an imaging agent to measure cerebral blood flow in patients with cerebral vascular disorders, FDA's Medical Imaging Drugs Advisory Committee concluded June 29.